Human Immunoglobulin E specific for Bet v 1 (IgE-Bet v 1)

Human Immunoglobulin E (IgE) specific for Bet v 1 is the primary immunological mediator of birch pollen allergy, one of the most prevalent seasonal allergies in temperate climates. Bet v 1 is the major allergen of birch pollen, and the production of specific IgE antibodies against it leads to the sensitization of mast cells and basophils via the high-affinity FcεRI receptor (Pahr et al., 2012). Upon re-exposure to birch pollen, the Bet v 1 allergen cross-links these surface-bound IgE molecules, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Gould & Sutton, 2008). This physiological cascade results in the clinical symptoms of allergic rhinitis, conjunctivitis, and potentially allergic asthma. Furthermore, due to the structural homology between Bet v 1 and proteins found in various fruits and vegetables, these IgE antibodies often cross-react, causing pollen-food allergy syndrome, also known as oral allergy syndrome (Biedermann et al., 2019). Therapeutic strategies focus on neutralizing these antibodies using anti-IgE biologics or modifying the immune response through allergen-specific immunotherapy to favor the production of protective IgG4 antibodies (Valenta et al., 2019). Measurement of Bet v 1-specific IgE levels remains a cornerstone for both the diagnosis of birch allergy and the monitoring of patient response to desensitization treatments.

Other names

Anti-Bet v 1 IgEBirch pollen-specific IgEBet v 1-specific IgEsIgE to Bet v 1

Drugs targeting this molecule typically work through two primary modalities: monoclonal antibodies like Omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils (Gould & Sutton, 2008; FDA, 2023). Alternatively, allergen-specific immunotherapy (AIT) involves the controlled administration of the Bet v 1 allergen to induce immunological tolerance, which promotes the production of 'blocking' IgG4 antibodies that compete with IgE for allergen binding and reduces the overall synthesis of allergen-specific IgE (Valenta et al., 2019).